Gilead Sciences Inc. Third Quarter Earnings Sneak Peek

S&P 500 (NYSE:SPY) component Gilead Sciences, Inc. (NASDAQ:GILD) will unveil its latest earnings on Thursday, October 27, 2011. Gilead Sciences is a biopharmaceutical company which discovers, develops and commercializes therapies for viral diseases, infectious diseases and cancer.

Gilead Sciences, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for net income of 96 cents per share, a rise of 12.9% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from 98 cents. Between one and three months ago, the average estimate moved down. It has been unchanged at 96 cents during the last month. For the year, analysts are projecting profit of $3.74 per share, a rise of 6.6% from last year.

Past Earnings Performance: Last quarter, the company missed estimates by one cent, coming in at net income of 95 cents per share against an estimate of profit of. In the first quarter, the company also missed expectations.

Investing Insights: has a Stock Chart Technical Analysts Dream About.

Wall St. Revenue Expectations: Analysts are projecting a rise of 8.8% in revenue from the year-earlier quarter to $2.11 billion.

Analyst Ratings: Analysts are bullish on this stock with 19 analysts rating it as a buy, none rating it as a sell and seven rating it as a hold.

A Look Back: In the second quarter, profit rose 4.8% to $746.2 million (93 cents a share) from $712.1 million (79 cents a share) the year earlier, but fell short analyst expectations. Revenue rose 10.9% to $2.14 billion from $1.93 billion.

Key Stats:

A year-over-year revenue increase in the second quarter snapped a streak of two consecutive quarters of revenue declines. Revenue fell 7.7% in the first quarter and 1.7% in the fourth quarter of the last fiscal year.

The increase in profit in the second quarter broke a streak of two consecutive quarters of year-over-year profit decreases. The figure dropped 23.8% in the first quarter and 21.5% in the fourth quarter of the last fiscal year.

Competitors to Watch: GlaxoSmithKline plc (NYSE:GSK), Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Bristol Myers Squibb Co. (NYSE:BMY), Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), Trimeris, Inc. (NASDAQ:TRMS), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and Hemispherx BioPharma, Inc (AMEX:HEB).

Stock Price Performance: During August 25, 2011 to October 21, 2011, the stock price had risen $3.41 (9%) from $38.06 to $41.47. The stock price saw one of its best stretches over the last year between March 1, 2011 and March 9, 2011 when shares rose for seven-straight days, rising 8% (+$3.09) over that span. It saw one of its worst periods between April 4, 2011 and April 12, 2011 when shares fell for seven-straight days, falling 3.9% (-$1.67) over that span. Shares are up $5.23 (+14.4%) year to date.

(Source: Xignite Financials)

Investing Insights: has a Stock Chart Technical Analysts Dream About.